Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity

Anti-cancer drugs

Volumn 26, Issue 2, 2015, Pages 160-166

  Jorvig, Jessica E ^a   Chakraborty, Arup ^a  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SESQUITERPENE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; ZERUMBONE;

ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MALE; METABOLIC NETWORKS AND PATHWAYS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SESQUITERPENES; STAT3 TRANSCRIPTION FACTOR;

EID: 84934297288     PISSN: None     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000171     Document Type: Article

References (0)